- Home
- SWVL vs SCYX Comparison
SWVL vs SCYX Comparison
Compare SWVL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- SCYX
- Stock Information
- Founded
- SWVL 2017
- SCYX 1999
- Country
- SWVL United Arab Emirates
- SCYX United States
- Employees
- SWVL N/A
- SCYX N/A
- Industry
- SWVL Business Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- SCYX Health Care
- Exchange
- SWVL Nasdaq
- SCYX Nasdaq
- Market Cap
- SWVL 30.1M
- SCYX 24.6M
- IPO Year
- SWVL N/A
- SCYX 2014
- Fundamental
- Price
- SWVL $3.07
- SCYX $0.58
- Analyst Decision
- SWVL
- SCYX Strong Buy
- Analyst Count
- SWVL 0
- SCYX 1
- Target Price
- SWVL N/A
- SCYX $3.00
- AVG Volume (30 Days)
- SWVL 10.2K
- SCYX 482.6K
- Earning Date
- SWVL 09-08-2025
- SCYX 11-05-2025
- Dividend Yield
- SWVL N/A
- SCYX N/A
- EPS Growth
- SWVL N/A
- SCYX N/A
- EPS
- SWVL N/A
- SCYX N/A
- Revenue
- SWVL $19,329,423.00
- SCYX $2,932,000.00
- Revenue This Year
- SWVL N/A
- SCYX $368.39
- Revenue Next Year
- SWVL N/A
- SCYX $123.36
- P/E Ratio
- SWVL N/A
- SCYX N/A
- Revenue Growth
- SWVL N/A
- SCYX N/A
- 52 Week Low
- SWVL $2.40
- SCYX $0.57
- 52 Week High
- SWVL $7.50
- SCYX $1.49
- Technical
- Relative Strength Index (RSI)
- SWVL 47.74
- SCYX 23.18
- Support Level
- SWVL $3.01
- SCYX $0.58
- Resistance Level
- SWVL $3.25
- SCYX $0.62
- Average True Range (ATR)
- SWVL 0.13
- SCYX 0.04
- MACD
- SWVL 0.01
- SCYX -0.00
- Stochastic Oscillator
- SWVL 26.15
- SCYX 9.31
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.